Literature DB >> 30237053

Frequent issues and lessons learned from EuroFlow QA.

Tomas Kalina1, Nadezda Brdickova2, Hana Glier3, Paula Fernandez3, Marieke Bitter4, Juan Flores-Montero5, Jacques J M van Dongen6, Alberto Orfao5.   

Abstract

EuroFlow Quality Assessment was designed to provide a feedback on the quality of the standardization effort in executing the EuroFlow protocols for sample preparation and instrument setup. It was first beta-tested by the members of the EuroFlow consortium internally (2010-2013) and opened to the external participants from 2015 onwards. The goal of participation in the EuroFlow QA is to evaluate whether the technical quality of the data generated by the laboratory is comparable to the data of the EuroFlow members and thus if a non-EuroFlow member participant can use the EuroFlow reference sample database for his own patient evaluation. Also it assesses whether data are sufficiently standardized for automated population gating and alarm notification. By spring 2018, a total 87 laboratories from 32 countries on five continents have registered for the EuroFlow QA program. We evaluated 163 results of 2015-2016 QA rounds, where we noted clear improvement in the score of first-time participants (median score of 91% correct) when they participated second time or later (median score of 94% correct, p = 0,017), which was comparable to EuroFlow member scores (median score of 97% correct). Among frequent mistakes, we found non-adherence to the EuroFlow protocols (improper reagent used), improper gating and some compensation issues. In summary, we show that EuroFlow QA has a positive impact on improvement of standardized data quality of non-member laboratories adhering to the EuroFlow standard operating procedures and reagent panels.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EuroFlow; Flow cytometry; Quality assessment scheme; Standardization

Year:  2018        PMID: 30237053     DOI: 10.1016/j.jim.2018.09.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  13 in total

1.  Standardization procedure for flow cytometry data harmonization in prospective multicenter studies.

Authors:  Lucas Le Lann; Pierre-Emmanuel Jouve; Marta Alarcón-Riquelme; Christophe Jamin; Jacques-Olivier Pers
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

Review 2.  Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation.

Authors:  In-Suk Kim
Journal:  Blood Res       Date:  2020-07-31

Review 3.  Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.

Authors:  Irene Della Starza; Sabina Chiaretti; Maria S De Propris; Loredana Elia; Marzia Cavalli; Lucia A De Novi; Roberta Soscia; Monica Messina; Antonella Vitale; Anna Guarini; Robin Foà
Journal:  Front Oncol       Date:  2019-08-07       Impact factor: 6.244

4.  EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System.

Authors:  Jacques J M van Dongen; Mirjam van der Burg; Tomas Kalina; Martin Perez-Andres; Ester Mejstrikova; Marcela Vlkova; Eduardo Lopez-Granados; Marjolein Wentink; Anne-Kathrin Kienzler; Jan Philippé; Ana E Sousa; Menno C van Zelm; Elena Blanco; Alberto Orfao
Journal:  Front Immunol       Date:  2019-06-13       Impact factor: 7.561

5.  The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System.

Authors:  Mirjam van der Burg; Tomas Kalina; Martin Perez-Andres; Marcela Vlkova; Eduardo Lopez-Granados; Elena Blanco; Carolien Bonroy; Ana E Sousa; Anne-Kathrin Kienzler; Marjolein Wentink; Ester Mejstríková; Vendula Šinkorova; Jan Stuchly; Menno C van Zelm; Alberto Orfao; Jacques J M van Dongen
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

6.  Conjunctival HLA-DR Expression and Its Association With Symptoms and Signs in the DREAM Study.

Authors:  Neeta S Roy; Yi Wei; Yinxi Yu; Gui-Shuang Ying; Eric Kuklinski; Brendan Barry; Maureen G Maguire; Reza Dana; Mary Brightwell-Arnold; Penny A Asbell
Journal:  Transl Vis Sci Technol       Date:  2019-08-21       Impact factor: 3.283

7.  Improved Standardization of Flow Cytometry Diagnostic Screening of Primary Immunodeficiency by Software-Based Automated Gating.

Authors:  Eleni Linskens; Annieck M Diks; Jana Neirinck; Martín Perez-Andres; Emilie De Maertelaere; Magdalena A Berkowska; Tessa Kerre; Mattias Hofmans; Alberto Orfao; Jacques J M van Dongen; Filomeen Haerynck; Jan Philippé; Carolien Bonroy
Journal:  Front Immunol       Date:  2020-11-02       Impact factor: 7.561

8.  Standardization of Workflow and Flow Cytometry Panels for Quantitative Expression Profiling of Surface Antigens on Blood Leukocyte Subsets: An HCDM CDMaps Initiative.

Authors:  Daniela Kužílková; Joan Puñet-Ortiz; Pei M Aui; Javier Fernández; Karel Fišer; Pablo Engel; Menno C van Zelm; Tomáš Kalina
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

9.  Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels.

Authors:  Łukasz Sędek; Juan Flores-Montero; Alita van der Sluijs; Jan Kulis; Jeroen Te Marvelde; Jan Philippé; Sebastian Böttcher; Marieke Bitter; Joana Caetano; Vincent H J van der Velden; Edwin Sonneveld; Chiara Buracchi; Ana Helena Santos; Margarida Lima; Tomasz Szczepański; Jacques J M van Dongen; Alberto Orfao
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

10.  Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.

Authors:  Davine Hofste op Bruinink; Stefania Oliva; Lucie Rihova; Alexander Schmitz; Milena Gilestro; Jeroen Te Marvelde; Romana Kralova; Helle Høholt; Annemiek Broijl; Hans Erik Johnsen; Roman Hajek; Mario Boccadoro; Pieter Sonneveld; Paola Omedè; Vincent H J Van der Velden
Journal:  Haematologica       Date:  2020-10-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.